{
    "nct_id": "NCT03897881",
    "official_title": "A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)",
    "inclusion_criteria": "* Resectable cutaneous melanoma metastatic to a lymph node and at high risk of recurrence\n* Complete resection within 13 weeks prior to the first dose of pembrolizumab\n* Disease free at study entry (after surgery) with no loco-regional relapse or distant metastasis and no clinical evidence of brain metastases\n* Has an formalin fixed paraffin embedded (FFPE) tumor sample available suitable for sequencing\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1\n* Normal organ and marrow function reported at screening\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior malignancy, unless no evidence of that disease for at least 5 years prior to study entry\n* Prior systemic anti-cancer treatment (except surgery and interferon for thick primary melanomas. Radiotherapy after lymph node dissection is permitted)\n* Live vaccine within 30 days prior to the first dose of pembrolizumab\n* Transfusion of blood or administration of colony stimulating factors within 2 weeks of the screening blood sample\n* Active autoimmune disease\n* Immunodeficiency, systemic steroid therapy, or any other immunosuppressive therapy within 7 days prior to the first dose of pembrolizumab\n* Solid organ or allogeneic bone marrow transplant\n* Pneumonitis or a history of (noninfectious) pneumonitis that required steroids\n* Prior interstitial lung disease\n* Clinically significant heart failure\n* Known history of human immunodeficiency virus (HIV)\n* Known active hepatitis B or C\n* Active infection requiring treatment",
    "miscellaneous_criteria": "Key"
}